Mengyang Di

19PUBLICATIONS
68CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersAged care nursing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 14, 2026
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

|Jul 17, 2026
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

|Apr 27, 2026
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

|Mar 19, 2026
Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Grace Baek, Gaurav Varma, Samuel Yamshon

|Nov 21, 2025
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.

Tycel Phillips, Mengyang Di, Taavy A Miller

|Jun 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Christina Poh, Jenna M Voutsinas, Mazyar Shadman

Pageof 4

Frequent Collaborators

5 joint publications

Mazyar Shadman

5 joint publications

Stephen D Smith

4 joint publications

Adam J Olszewski

4 joint publications

Ryan C Lynch